Add To Watchlist
Share URL
About The Company
Description
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.
Read More
Overview
Value
2
Growth
79
Health
53
Management
47
Analyst Opinion
80
Total
52
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Has a low level of debt
- Low risk of bankruptcy
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings growth has slowed down recently
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Price-to-earnings ratio of 402.0 is higher than the market average (19.6x) 0
Market Peers
CAMX.ST
Key Figures
PE Ratio (TTM)
402.05
Margin Of Safety (DCF)
-124.05%
Revenue Growth (5 Year Average)
24.55%
Ratings Consensus
Buy
Share Buybacks
-3.36%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
2
- ✘ Estimated intrinsic-value of NaN undefined SEK is lower than current price ( 209.20 SEK)
- ✘ Price-to-earnings ratio of 402.0 is higher than the market average (19.6x)
- ✘ Free-cashflow-yeild of 0.12% is worse than the market average (4.7%)
- ✘ Margin-of-safety of -124.05% is worse than the market average (17.95%)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 206.8 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
402.05x
Free Cashflow Yeild
0.12%
PE/Earnings Growth
8.41
Price/Book
11.83x
Growth
Growth Score
79
- ✔ 5 Year Average Revenue growth of 24.55% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 21.56% is higher than the market average (14.48%)
- ✔ 5 Year Average Cashflow growth of 19.75% is higher than the market average (12.35%)
- ✘ Earnings growth has slowed this year
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
24.55%
Earnings Growth
21.56%
Cashflow Growth
19.75%
Health
Health Score
53
Altman Z Score
20.00
Piostroski Score
7.00
Debt/Equity
0.03x
Current Assets/Liabilities
3.19x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.04x
Management
Management Score
47
Average Buybacks/Dilution
-3.36%
Recent Buybacks/Dilution
1.79%
5 Year Price Volitility
24.69%
Return On Assets
-8.50%
Return On Capital Employed
-6.57%
Return On Equity
-10.84%
Return On Free Cashflow
37.99%
Return On Investments
N/A
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
SEK
Beta
Vol Avg
Ceo
Mr. Fredrik Tiberg
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
Ideon Science Park
City
Lund
State
Country
Zip
223 70
Phone
46 4 62 86 57 30
All financial data provided by FMP